Skip to main content

3-methylcrotonyl-CoA carboxylase deficiency: Clinical, biochemical, enzymatic and molecular studies in 88 individuals



Isolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine metabolism caused by mutations in MCCC1 or MCCC2 encoding the α and β subunit of MCC, respectively. The phenotype is highly variable ranging from acute neonatal onset with fatal outcome to asymptomatic adults.


We report clinical, biochemical, enzymatic and mutation data of 88 MCC deficient individuals, 53 identified by newborn screening, 26 diagnosed due to clinical symptoms or positive family history and 9 mothers, identified following the positive newborn screening result of their baby.


Fifty-seven percent of patients were asymptomatic while 43% showed clinical symptoms, many of which were probably not related to MCC deficiency but due to ascertainment bias. However, 12 patients (5 of 53 identified by newborn screening) presented with acute metabolic decompensations. We identified 15 novel MCCC1 and 16 novel MCCC2 mutant alleles. Additionally, we report expression studies on 3 MCCC1 and 8 MCCC2 mutations and show an overview of all 132 MCCC1 and MCCC2 variants known to date.


Our data confirm that MCC deficiency, despite low penetrance, may lead to a severe clinical phenotype resembling classical organic acidurias. However, neither the genotype nor the biochemical phenotype is helpful in predicting the clinical course.


Isolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency (MIM#s 210200 and 210210) is an autosomal recessive disorder of leucine metabolism[1]. The mitochondrial enzyme MCC (EC catalyzes the fourth step in the leucine catabolic pathway and belongs to the family of biotin-dependent carboxylases, including acetyl-CoA carboxylase (ACC), propionyl-CoA carboxylase (PCC) and pyruvate carboxylase (PC)[1]. MCC consists of an alpha and a beta subunit assembled into a α6β6 dodecamer. The larger α subunit harbours the biotin carboxylase (BC) domain and the biotin carboxyl carrier protein domain covalently bound with a biotin prosthetic group, while the smaller β subunit contains the carboxyltransferase (CT) domain.

Isolated MCC deficiency is caused by mutations in the MCCC1 (formerly MCCA) or the MCCC2 (formerly MCCB) gene coding for the α and β subunit, respectively[24]. Human MCCC1 has 19 exons and maps to chromosome region 3q25-q27, MCCC2 consists of 17 exons and has been located to chromosome region 5q12-q13[24]. A total of 49 MCCC1 and 52 MCCC2 mutations have been reported so far with the majority being missense mutations along with small insertions/deletions, nonsense, frameshift, and splice site mutations[212].

Increased urinary levels of 3-hydroxyisovaleric acid (3-HIVA) and 3-methylcrotonylglycine (3-MCG) are usually found in isolated MCC deficiency. Additionally, 3-hydroxyisovalerylcarnitine (C5OH) is characteristically present in blood and urine. Many patients also develop a severe secondary carnitine deficiency[1]. Surprisingly, MCC deficiency was found to be the most frequent organic aciduria detected in tandem mass spectrometry based newborn screening (NBS) programs in North America[13, 14], Europe[15, 16] and Australia[17].

The clinical picture of MCC deficiency is heterogeneous and often highly variable even within the same family[10, 18]. The phenotype ranges from neonatal onset with severe neurological involvement and even lethal cases[1921] to asymptomatic adults[3, 6, 11, 22]. Some patients develop an acute metabolic crisis usually triggered by intercurrent infections or introduction of a protein-rich diet in early childhood. Symptoms include vomiting, opisthotonus, involuntary movements, seizures, coma and apnoea typically associated with metabolic acidosis, hypoglycemia and in some cases mild hyperammonemia[3, 7, 2327]. Others present with neurological abnormalities such as seizures, muscular hypotonia or developmental delay[6, 18, 2831].

In contrast, the majority of children diagnosed by NBS have been reported to have remained asymptomatic so far[6, 7, 11, 32]. Moreover, several asymptomatic MCC-deficient mothers have been identified only by detection of abnormal metabolites in the neonatal-screening sample from their healthy babies[3, 6, 11, 22] and a number of asymptomatic affected siblings have been identified by family screening[3335]. The comparative analysis of published case reports with German NBS data indicated that probably less than 10% of affected individuals develop symptoms[6]. Therefore, MCC deficiency may be considered to be a genetic condition with low penetrance.

Therapeutic approaches comprise supplementation with oral L-carnitine and a diet modestly restricted in leucine but the efficacy of these approaches is unproven[36].

Here we summarize clinical, biochemical, enzymatic and molecular genetic data of 88 MCC-deficient individuals, present an update of all MCCC1 and MCCC2 mutations reported to date including 15 novel MCCC1 and 16 novel MCCC2 mutations and show expression studies of 10 missense mutations and one small deletion.

Patients and methods


Eighty-eight subjects with MCC deficiency from 78 families (10 sib-pairs) were included in this study (Tables1,2,3 and4). Cultured fibroblasts (n = 69) or genomic DNA (n = 16) from 85 individuals were sent to our laboratory for confirmation of MCC deficiency. In the remaining 3 subjects mutation analysis was performed in a genetic laboratory in the USA. Forty-five subjects were male, 40 were female; the sex of 3 individuals was not reported. Of the 88 individuals 45 (51%) were Caucasian, 27 (31%) Turkish, 8 (9%) Arab, 6 (7%) Asian, one (1%) African-American, and one patient (1%) was of mixed African Caucasian ancestry.

Table 1 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency 53 Individuals identified by newborn screening without (n = 36) and with (n = 13) reported symptoms (n = 4 without clinical details)
Table 2 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency 18 individuals identified by selective metabolic screening due to clinical symptoms (n = 17, no clinical details in n = 1)
Table 3 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency 8 individuals identified by family screening (asymptomatic individuals (n = 3), symptomatic individuals (n = 3), no clinical data (n = 2))
Table 4 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency Mothers identified following the positive newborn screening result of their offspring (n = 9)

Clinical, biochemical, enzymatic or mutation data of 32 individuals have been reported earlier [proband 20-32a, 33-34, 36-43a, 44 and 46[11], 30[23], 35a and 35b[30], 42[37], 44[38], 50[28], 80[9], 81[39], 96a and 96c[10], and 136[26]].

Clinical data

A questionnaire was designed and sent out to the treating physicians. This questionnaire specifically addressed the mode of diagnosis, clinical symptoms, the psychomotor development, biochemical markers and long-term treatment regimens. Additionally, in some cases medical reports that were sent in together with the diagnostic samples were available and used for clinical data collection.

Cell lines and enzyme assays

Fibroblasts were cultured in a culture medium containing 10% foetal calf serum, and the activities of PCC and MCC were assayed simultaneously in crude fibroblast homogenates by measuring the incorporation of 14C-bicarbonate into acid-non-volatile products as described earlier[40].

MCCC1 and MCCC2 mutation analysis by RT-PCR and genomic PCR

After obtaining informed consent mutation analysis was performed in 83 individuals. The 5 individuals in whom no mutation analysis was performed were siblings of index cases and presented with a metabolite profile typical for MCC deficiency. In probands from whom RNA and DNA were available RT-PCR amplification and sequencing of the entire MCCC2 ORF was first performed and if no clearly pathogenic coding alterations were detected in MCCC2, the entire MCCC1 ORF was also analyzed. Identified mutations were confirmed by PCR amplification of genomic DNA. In individuals from whom only DNA was available amplification of all MCCC1 and MCCC2 exons and flanking intronic sequences from genomic DNA followed by direct sequencing was performed.

RNA and genomic DNA were extracted from cultured skin fibroblasts or peripheral blood leukocytes using the QIAamp® RNeasy or QIAamp® RNA Blood Mini Kit and the QIAamp® DNA Mini Kit (Qiagen AG, Basel, Switzerland), respectively. The RT-PCR reaction was performed using the One-Step RT-PCR kit (Qiagen AG, Basel, Switzerland) following the manufacturer’s instructions. First-strand MCCC1 and MCCC2 cDNA was amplified as described[2]. PCR products were sequenced in a thermocycler and analyzed with an ABI Prism 3100 Avant using the dye-terminator method (Applied Biosystem, Rotkreuz, Switzerland) according to the manufacturer’s instructions. To confirm mutations identified in RT-PCR products, a genomic fragment containing the corresponding exon was amplified using flanking intronic primers, and the PCR product was sequenced directly. In cases where only one of the two alleles could be identified in the standard RT-PCR product all exons and flanking intronic regions were sequenced. The sequences of all primers are available upon request.

To exclude that the identified missense mutations are common polymorphisms we amplified the relevant exons from genomic DNA of 100 controls (200 alleles).

Construction of wild type and mutant MCCC1 and MCCC2 expression vectors and transfections

The following mutations were introduced by site-directed mutagenesis into the existing wildtype MCCC1 and MCCC2 pCR Blunt II TOPO vector (Invitrogen, Basel, Switzerland): MCCC1 p.E288G, p.G379D, p.I434M and MCCC2 p.S39F, p.G118del, p.Y146N, p.H282R, p.V434L, p.A456V, p.G475R, p.S523G. All constructs were then transferred into the mammalian expression vector pTracer-CMV2 (Invitrogen, Basel, Switzerland) and seq-uenced for validation. For expression studies the constructs were transiently transfected into transformed cultured fibroblasts deficient in either MCCC1 (homozygous for c.1264_1265insG/p.Q422Rfs*10 or compound heterozygous for c.1264_1265insG/p.Q422Rfs*10 and c.1682-3A > G/p.N561Kfs*10) or MCCC2 (homozygous for c.127 C > T/p.Q43*) by electroporation as described[2]. The cells were harvested 48 hours later and assayed for MCC and PCC activity.

Western blot analysis of expressed proteins

Western blot analysis of proteins extracted from cells harvested 48 h after transfection was performed as described earlier[41]. For immunostaining of MCCC2 a commercially available antibody was used (Abnova). Antiserum for MCCC1 was produced by inoculating rabbits with peptides corresponding to the hydrophilic strech of the last 19 C-terminal amino acids (RHTPLVEFEEEESDKRESE) of human MCCC1 conjugated to keyhole limpet hemocyanin (Covance, Denver, Colorado). β-Actin was stained as control.

The biotin-containing MCC and PCC α-subunits and PC were also stained using streptavidin-alkaline phosphatase followed by colorimetric detection (Transcend™ Non-Radioactive Translation Detection Systems Kit, Promega, Dübendorf, Switzerland).

In silico prediction of functional relevance of identified mutations

The human MCCC1/2 enzyme has not been structurally characterized. Missense mutations were therefore interpreted structurally using the homologous structure of Pseudomonas aeruginosa MCC holoenzyme (PDB code 3U9T). Amino acid sequence alignment of MCCC1/2, ACC1/2, PCCα/β sequences was constructed using the ICM-Pro program (Molsoft, San Diego) with the implemented alignment algorithm. The protein sequences NG_008100.1 and NG_008882.1 [GenBank at the NCBI] were used as reference sequences for the alpha and beta subunit of MCC, respectively.


A comprehensive summary of clinical, biochemical, enzymatic and molecular genetic information on each patient is given in Tables1,2,3 and4.

Diagnosis of MCC deficiency was confirmed by assaying MCC and PCC activities in fibroblasts of 68 individuals. In 50 cell lines MCC activity was severely reduced to less than 5% of the median control value. In 16 further cell lines residual MCC activity varied between 5.1% and 20% and in 2 cell lines MCC activity was 31% and 34% of the control value. All cell lines had a highly increased PCC/MCC activity ratio of at least 7.1. From 20 subjects fibroblasts were not available and the diagnosis was confirmed by mutation analysis using genomic DNA.

Clinical data

Twenty-six individuals (30%) were diagnosed by selective metabolic screening (SMS) due to clinical symptoms (n = 18) or a positive family history (n = 8) while 53 individuals (60%) were identified by expanded NBS. Additionally, 9 mothers (10%) were diagnosed following a positive NBS result of their healthy offspring. In patients in whom a metabolic work-up was initiated due to clinical symptoms age at diagnosis ranged between one week and 13 years (median 1.5 years) (Table2). Patients identified by family screening had a median age at diagnosis of 3.75 years (range 1.5-17 years) (Table3), and mothers were diagnosed at a median age of 30.5 years (range 24-38 years) (Table4).

Clinical information was available from 80 individuals. Parental consanguinity was reported in 31 subjects with most parents being second-degree relatives. Fourty-four parents were non-consanguineous and of 13 individuals no information on consanguinity was available. Three children had deceased, two during an acute metabolic decompensation at the age of 33 days and 6 weeks, and the third, a 8-year-old girl with sudden cardiac death due to catecholaminergic polymorphic ventricular tachycardia (mutations in RyR2 gene).

In 34 (43%) of 80 subjects clinical symptoms were reported ranging from acute metabolic decompensation with ketoacidosis, hypoglycemia and encephalopathy to neuromuscular symptoms, mental retardation or attention deficit hyperactivity disorders (Figure1). Twelve patients, 5 of which were diagnosed by newborn screening, had at least one acute metabolic decompensation. The most common clinical symptoms of acute crises were vomiting and encephalopathy with impaired conciousness. Neurologic symptoms like seizures, metabolic stroke, hemiparesis and cerebral edema were less frequent. The most common laboratory findings were acidosis and hypoglycaemia. Among chronic symptoms mental retardation including speech retardation were the most common findings followed by seizures, muscular hypotonia, muscle weakness, muscle pain and failure to thrive. In 5 patients an attention deficit hyperactivity disorder was reported.

Figure 1

Clinical manifestation of 33 symptomatic individuals with MCC deficiency. One patient who died of sudden cardiac arrest at the age of 8 years was excluded from this figure as catecholaminergic ventricular tachycardia with mutations in the RyR2 gene was identified as a likely cause for the cardiac symptoms.

Thirty-five out of 61 (57%) living individuals of whom recent follow-up information was available or who had been followed for at least until the age of three years have remained asymptomatic. Notably, 25 (69%) of the 36 subjects identified by NBS of whom either recent information or follow-up data until the age of at least three years were available, have remained without symptoms.

Sixty-nine out of 75 individuals of whom information on treatment was available received dietary and/or medical therapy. Forty individuals were given a protein-restricted or leucine-restricted diet (which was stopped later in life in some cases) and in 23 a leucine-free amino acid mixture was administered at least temporarily. In 30 subjects oral biotin was given on a trial basis. 63 patients were supplemented with oral carnitine, and 10 patients received oral glycine.

Biochemical phenotype at diagnosis

Presence of C5OH in blood or dried blood spots and presence of elevated urinary excretion of 3-HIVA and 3-MCG at the time of diagnosis are shown in Tables1,2,3 and4. A biochemical phenotype characteristic for MCC deficiency with elevated excretion of 3-HIVA and/or 3-MCG, defined as more than twice the upper normal value, was found in 85% (68/80) of individuals. In 14% (11/80) only mildly elevated excretion was detected. In one patient (1%) no elevated excretion of 3-HIVA and 3-MCG was detected. Notably, 5 individuals including one patient reported earlier[39] did not excrete 3-MCG, the pathognomonic metabolite of MCC deficiency. However, one of these individuals showed massive excretion of 3-MCG when re-evaluated 6 months later.

C5OH in dried blood spots was highly elevated in 85% (66/78) and slightly (less than twice the upper normal value) elevated in 15% (12/78) of individuals. Low C5OH concentrations were not always linked with low urinary excretion of metabolites and vice versa.

In 43/68 individuals (63%) a secondary carnitine deficiency was present. Remarkably, 24 (60%) of those 40 children identified through NBS of whom information on free carnitine concentrations was available had decreased free carnitine levels already at the time of diagnosis or within the neonatal period. In 15 of them free carnitine concentration was below 5 μmol/l.

Mutation analysis

Of the 83 individuals in whom mutation analysis was performed, 31 had mutations in MCCC1 and 52 in MCCC2 (Tables1,2,3 and4). Forty-eight probands were found to be homozygous (12 for MCCC1 mutations and 36 for MCCC2 mutations) while 28 were compound heterozygous (15 for MCCC1 mutations and 13 for MCCC2 mutations). In 5 of these patients RT-PCR results showed exon skipping either for one or both alleles, but the underlying genomic mutation could not be identified. In the remaining 7 subjects (4 MCCC1 and 3 MCCC2) it was not possible to detect a second mutation in spite of sequencing all exons and flanking intronic sequences. However, the mutant allele identified appeared to be homozygous in RT-PCR, but was clearly heterozygous in genomic DNA. This suggests that the steady state level of mRNA from the second allele was not detectable as would be the case for a promoter mutation or an intragenic deletion or insertion missed by genomic PCR.

We identified a total of 15 novel MCCC1 and 16 novel MCCC2 mutations (shown in bold in Tables5 and6). The 15 novel MCCC1 mutations comprise 7 missense, 2 nonsense, 1 splice site and 5 frameshift mutations (5 due to small deletions and one due to a small insertion). The 16 novel MCCC2 variants include 11 missense and 4 splice site mutations and 1 deletion of a single amino acid.

Table 5 Overview on 64 MCCC1 mutant alleles and their consequences
Table 6 Overview on 68 MCCC2 mutant alleles and their consequences

Expression studies and Western blot analysis

The functional consequences of three MCCC1 (p.E288G, p.G379D, p.I434M) and 8 MCCC2 (p.S39F, p.G118del, p.Y146N, p.H282R, p.V434L, p.A456V, p.G475R and p.S523G) mutations were investigated by expression studies (Table7). The MCCC1 p.E288G and p.G379D mutations showed no residual activity while the p.I434M mutant allele yielded on average 46% of MCC1 wildtype activity.

Table 7 Expression of MCCC1 and MCCC2 wildtype and mutant alleles

Only one of the MCCC2 mutations, p.A456V, showed virtually no enzyme activity whereas seven mutations were found to have residual activity ranging on average from 9 to 84% of MCC2 wildtype activity. Western blot analysis of the expressed proteins revealed virtually wildtype levels for the MCCC1 p.I434M protein while the levels of MCCC1 p.E288G and MCCC1 p.G379D proteins were severely reduced or not detectable (Figure2). Five of the 8 expressed MCCC2 proteins (p.Y146N, p.H282R, p.A456V, p.G475R and p.S523G) were detected at normal or only slightly reduced levels, while the p.S39F and p.V434L protein levels were severely reduced and no protein was detectable after transfection with the p.G118del construct (Figure3).

Figure 2

Western blot analysis of expressed MCCC1 wildtype and mutant proteins. Constructs with MCCC1 wildtype and 3 mutant cDNAs in pTracer vector were transfected into MCCC1 deficient reference cell lines by electroporation and harvested 48 hours later for Western blot analysis. 50 μg of protein were used per lane. The MCCC1 subunit was visualized by a) immunostaining using β-actin (4 μg) as control, or by b) colorimetric reaction after coupling with avidin-alkaline phosphatase. Transfection with an empty vector (vector only) was used as a negative control. For further details see “Methods”.

Figure 3

Western blot analysis of expressed MCCC2 wildtype and mutant proteins. Constructs with MCCC2 wildtype and 8 mutant cDNAs in pTracer vector were transfected into MCCC2 deficient reference cell lines by electroporation and harvested 48 hours later for Western blot analysis. 50 μg of protein were used per lane. The MCCC2 subunit was visualized by immunostaining using β-actin (6 μg) as control. Transfection with an empty vector (vector only) was used as a negative control. For further details see “Methods”.


This study summarizes clinical, biochemical, enzymatic and mutation data on 88 MCC deficient individuals and summarizes all MCCC1 and MCCC2 mutations described so far.

Clinical phenotype

MCC deficiency has been described as a genetic condition with low clinical penetrance[6]. Results of a comparative analysis of case reports with NBS data reported by Stadler and co-workers[6] suggest that less than 10% of affected individuals ever develop minor symptoms and only less than 1 to 2% might have a risk for severe adverse outcome. In their study all 14 individuals diagnosed by NBS remained asymptomatic during a follow-up period of 1.75 to 6.5 years. In contrast, in our study only 69% of the 36 subjects identified by NBS with a follow-up of at least 3 years have stayed completely asymptomatic while the remainder (31% =11) developed clinical symptoms including various neurologic symptoms as well as at least one acute metabolic decompensation in 5 children. This indicates that early diagnosis with concomitant early initiation of therapy and counselling of parents cannot prevent a clinical manifestation in all cases. However, our data have to be interpreted with caution, since the source of patients being those sent to a diagnostic referral laboratory may lead to a selection bias in favour of symptomatic individuals since it can be assumed that samples for confirmatory diagnosis are more likely to be obtained from symptomatic subjects than from asymptomatic individuals. Additionally, the clinical phenotype of MCC deficiency is still not well-defined.

In our study population the most common clinical features were acute episodes of metabolic acidosis with vomiting, hypoglycemia and acidosis, muscular symptoms such as muscular hypotonia, muscle weakness and muscle pain and neurological abnormalities including developmental delay and seizures as well as attention deficit hyperactivity disorders (Tables1,2,3 and4). The acute metabolic crises reported in 12 patients are likely to be caused by the underlying metabolic defect. However, the causative attribution of all other clinical signs, especially of unspecific chronic neurologic symptoms such as mental retardation, attention deficit disorders and fatigue to MCC deficiency remains questionable. It could be speculated that these symptoms might as well be caused by undiagnosed genetic defects other than MCC deficiency. Such an additional genetic disorder –though unprobable- would be more likely in individuals that are the product of a consanguineous union; thus a higher share of symptomatic individuals would be expected in this subgroup when compared to subjects whose parents are reported not to be consanguineous. However, no significant difference in the clinical manifestation rate between the two subgroups could be shown (41% symptomatic patients in both subgroups, 12 of 29 individuals with reported parental consanguinity versus 18 of 44 subjects with parents reported not to be consanguineous).

Of the three lethal cases in our study cohort, two could be attributed to a severe metabolic decompensation due to MCC deficiency. The sudden cardiac death of a 9 year old girl was shown to be caused by catecholaminergic polymorphic ventricular tachycardia with mutations in the RyR2 gene. Thus, in the cohort of 80 individuals of whom clinical information was available, lethality that may be associated with MCC deficiency was 2.5% (2/80).

Altogether, though the share of individuals with clinical symptoms was higher in our study population, our data underline the observation of Stadler and co-workers[6] that compared to other organic acidemias, individuals with MCC deficiency appear to have a significantly higher tolerance toward metabolic stress; even complete absence of MCC activity seems to cause clinical manifestations only in association with environmental triggering factors in a rather small subgroup of individuals. Dietetic treatment is usually not required. However, considering the frequency of carnitine deficiency in our study population, regular monitoring of free carnitine concentrations and – if necessary - oral carnitine substitution seems to be warranted. Also, an emergency regimen during intercurrent illness may be advisable.

Biochemical phenotype/MCC activity

As shown in Tables1,2,3 and4 the vast majority of individuals displayed a typical biochemical phenotype with accumulation of metabolites characteristic for MCC deficiency in both blood and urine at the time of diagnosis. Mild elevations of one or more metabolites were the exception and were not more common in asymptomatic individuals. A completely unremarkable urine organic acid pattern was detected in only one woman. However, the concentration of C5OH in her blood was clearly elevated at the same time.

The phenomenon that mutations may cause a clear biochemical phenotype in otherwise asymptomatic individuals is well known from other inborn errors of metabolism implemented in expanded NBS such as isovaleric acidemia[42] or medium-chain acyl-CoA dehydrogenase deficiency[43]. From the data available in this study we were able to confirm earlier observations that in MCC deficiency there is no apparent association between the biochemical and the clinical phenotype and that a mild biochemical phenotype does not seem to be a predictor of a mild clinical expression[2, 6, 11]. Furthermore, we have recently shown that also individuals who are carriers of a single mutation at the MCCC1 locus and have residual MCC activity greater than 20% of control may present with a mild biochemical phenotype characteristic for MCC deficiency[12].

In all but two individuals MCC activity in fibroblasts was severely reduced combined with normal activity of PCC. As for the biochemical phenotype, we were not able to demonstrate a correlation between the residual enzyme activity and the clinical phenotype. When individuals with a less severe deficiency of MCC as indicated by a PCC/MCC ratio of < 50 were compared to a subgroup with a more severe deficiency and a ratio of > 50, the manifestation of clinical symptoms was not significantly more common in the latter group (40% (6/15) versus 47% (22/47), respectively).

Molecular heterogeneity

Molecular genetic analysis of 83 subjects enrolled in the current study revealed a total of 31 new MCCC1 (n = 15) and MCCC2 (n = 16) mutations considered to be causative of MCC deficiency. This brings up the total of mutations published to date to 64 for MCCC1 and 68 for MCCC2 (Tables5 and6)[212].

In our study cohort MCCC2 mutations were 1.7 times more common than MCCC1 mutations (63% versus 37%, respectively).

Tables5 and6 illustrate a broad genetic heterogeneity at both the MCCC1 and MCCC2 locus. Mutations are distributed along almost the entire coding regions of both genes with the exception of exon 2 of both the MCCC1 and MCCC2 gene which do not host any mutations.

The majority of mutations are private. Notably, in our cohort of 78 families only 5 MCCC1 and 10 MCCC2 mutations have been found in more than one family. The most common mutation was the p.R385S mutation in MCCC1 which was found in 8 individuals and 9 alleles. This missense mutation has been shown to have a dominant negative effect in the presence of the wild type allele and may lead to biochemical and clinical abnormalities in heterozygous individuals[44]. However, in agreement with earlier reports p.R385S appears not to be a predictor of a particular phenotype and has been found in severely affected patients as well as in asymptomatic individuals (this study,[2, 3, 44].

Another recurring mutation was c.1526delG (p.C509Sfs*14) which was the only mutation found in all 3 individuals from the Faroe Islands suggesting that this is a founder mutation.

Novel mutations

Among the novel mutations identified in this study (shown in bold in Tables5 and6) the most common were missense mutations (n = 18). Frameshift (n = 5) and splice site mutations (n = 5) were more frequent than nonsense mutations (n = 2) and small deletions (of a single amino acid) (n = 1).

We assume deleterious functional consequences for the frameshift mutations MCCC1 c.658_662delTCAGA (p.S220Tfs*15), c.1193_1194delTG (p.V398Gfs*19), c.1820delG (p.S607Ifs*5), c.2009_2043del35 (p.A670Dfs*34), c.2123dupA (p.H708Qfs*8)], the splice site mutations MCCC1 c.639 + 2 T > A (p.S164Rfs*3); MCCC2 c.903 + 6_903 + 9delTACG (p.?), c.1073-12 C > G (p.G358Vfs*6 + p.G358Afs*12), c.1149 + 1 G > T (p.?), c.1149 + 5 G > C (p.?)] and the nonsense mutations MCCC1 c.1114 C > T (p.Q372*), c.1882 G > T (p.E628*)] because they result in truncated proteins lacking functionally important domains such as the BC (in MCCC1) or CT (in MCCC2) domains[2, 45].

The MCCC2 splice site mutation c.1073-12 C > G is interesting since sequence analysis of cDNA of patient #107 revealed two overlapping sequences. One transcript showed exon 12 and 13 skipping, while the other transcript contained an inframe insertion of a 48 bp sequence from intron 11. No wildtype transcript could be detected. It is conceivable that the c.1073-12 C > G mutation creates a cryptic splice site resulting in partial skipping of exons 12 and 13 and in the partial insertion of an additional exon.

Among the novel MCCC1 missense mutations all variants [p.M65L, p.G180V, p.A268D, p.E288G, p.G379D, p.I434M, p.V439M] change residues within the BC domain, while all novel MCCC2 missense mutations [p.C131F, p.Y146N, p.K152T, p.Y169D, p.I200N, p.G220E, p.P224L, p.G237D, p.V434L, p.G475R, p.G475R] affect the CT domain of the MCCC2 protein. During the final stage of this manuscript preparation, the crystal structure of P. aeruginosa MCC holoenzyme, with >50% sequence identity to the human counterpart (Additional file1: Figure S1 Additional file2: Figure S2), was reported[46]. The structure reveals a markedly different holoenzyme architecture compared to other biotin-dependent enzymes, hence providing an unprecedented opportunity to understand MCCC1/2 missense mutations in the protein context. We rationalize that the reported variants are very likely to affect protein function for the following reasons: 1) No other alterations in the MCCC1 and MCCC2 gene have been found despite sequencing of the complete coding regions of both genes in all individuals carrying one of those mutations; 2) Amino acid sequence alignments revealed that all but one MCCC2 c.599 T > A (p.I200N)] of the nucleotide changes affect highly conserved residues across species (PolyPhen2,, and many are also conserved among other biotin-dependent enzymes (Additional file1: Figure S1, Additional file2: Figure S2); 3) A majority of the mutations are mapped onto the catalytic core of the MCCC1 BC domain and the substrate binding region of the MCCC2 CT domain (yellow spheres in Figure4A), suggesting their functional importance; 4) Most of the missense mutations alter the physicochemical properties of the amino acid position (e.g. replacing small with bulky, unipolar with polar, or uncharged with charged residues) and hence are likely to affect the local molecular environment; 5) None of these 19 variants is present in the 1000 Genomes Project dataset (; 6) It is of note that some MCCC1/2 missense mutations, affecting residues at the inter-subunit interface (Figure4B and C), may affect not only the corresponding domain fold but also disrupt the assembly of the α and β subunits into the functional hetero-dodecamer.

Figure 4

Mapping of missense mutations onto the P. aeruginosa MCC holoenzyme structure. (A) Mapping of the novel missense mutations (yellow spheres) onto the P. aeruginosa MCC holoenzyme structure (PDB code 3U9T), showing that they are clustered in the BC domain of MCCC1 (pink) or the CT domain of MCCC2 (green). (B) and (C) Mutation sites of Asn200, Gly220, Pro224 and Gly475 are located at the interface between two MCCC2 subunits (coloured green and purple). (D) Structural environment of the MCCC1 Glu288 and Gly379 mutation sites. All the residues shown in sticks are conserved between the human and P. aeruginosa enzymes. The Glu288-Arg444 ionic interaction is indicated by dashed lines.

Expression data

So far, functional consequences of only 4 MCCC1 and 8 MCCC2 mutant alleles have been proven by expression in a mammalian expression system[2, 11]. In this study we expressed 3 further MCCC1 and 8 MCCC2 mutations (Table7) including those expected to show residual enzyme activity based on studies in fibroblasts. Expression of two of the 3 MCCC1 [p.E288G and p.G379D] and one of the 8 MCCC2 [p.G118del] mutants resulted in severely reduced MCC activity and protein levels on Western blot analysis confirming deleterious consequences of these mutations on enzyme function and protein stability. Glu288 and Gly379 in MCCC1 are highly conserved residues in the BC domains among biotin-dependent enzymes (Additional file1: Figure S1). In the P. aeruginosa MCC holoenzyme structure, Glu288 forms an ionic pair interaction (Glu288-Arg444) to hold two secondary structure elements together, as observed in the homologous structures of ACC1 (Glu427-Arg604; PDB code 2YL2), ACC2 (Glu533-Arg710; 3GLK) and PCCα (Glu302-Arg459; 3N6R). Gly379 is expected to be at an invariant position at the beginning of a nearby β-strand, directly facing the aforementioned arginine residue. Mutations at Glu288 and Gly379 therefore may disrupt the packing of these secondary structure elements (Figure4D).

Deleterious effects of two further MCCC2 mutant alleles [p.H282R and p.A456V] were shown by severely reduced MCC activities of less than 13% of simultaneously expressed wildtype activity. However, in both cases protein levels were normal, and the two affected residues His282 and Ala456 are located at the monomeric surface, indicating that these mutations do not affect the stability of the protein. Expression of all other mutant alleles [MCCC1 p.I434M, MCCC2 p.S39F, p.Y146N, p.V434L, p.G475R and p.S523G] yielded considerable levels of residual MCC activity (Table7). The equivalent of MCCC1 Ile434 in other biotin-dependent carboxylases can be Phe or Leu (Additional file2: Figure S2), suggesting that substitution to a Met (similar size to Phe and Leu) in the p.I434M mutation may well be tolerated. All mutated residues from the 7 MCCC2 missense constructs (p.S39F, p.Y146N, p.282R, p.V434L, p.A456V, p.G475R, p.S523G) are at least partially exposed to the surface of the monomer, and not buried within the enzymatic core. Fibroblasts of 4 individuals (No 69, 80, 126 and 127) each homozygous for one of these mutations also showed residual enzyme activity, which was, however, much lower (6.2 – 31% of the median control value) than the activities of the expressed mutant alleles (39% - 77% of simultaneously expressed wildtype activity). Inspite of the high MCC activities after expression Western blot analysis revealed severely reduced protein levels in 2 cases (MCCC2 p.S39F, p.V434L). Normal levels of protein were expressed by two other mutant alleles (MCCC2 p.S523G, p.G475R). Even more drastic differences were found between MCC activity of the expressed protein (45%-89%) and that of fibroblasts (3.2% - 7.6%) that are compound heterozygous for the MCCC1 mutation p.I434M and MCCC2 mutations p.Y146N and p.S523G (individuals No 56, 66 and 74). Thus, expression studies may not demonstrate/identify the specific functional abnormalities for at least some of the mutant alleles with residual enzyme activity. However, no other mutations were found despite sequencing of the complete coding region of both MCC genes.

Genotype-phenotype correlations

Our data confirm previous studies reporting no clear genotype-phenotype correlation in MCC deficiency[3, 6, 11] suggesting that factors other than the genotype at the MCC loci have a major influence on the clinical phenotype[11]. In line with this we identified clinically asymptomatic female adults carrying null mutations in homozygosity and siblings of which one was asymptomatic and the other showed neurologic symptoms compatible with influence of environmental factors on the clinical outcome of affected individuals.

None of the mutations found in asymptomatic individuals with MCC deficiency detected by NBS was prevalent in this group, which is in contrast to other inborn errors of metabolism such as isovaleric acidemia[42] or medium-chain acyl-CoA dehydrogenase deficiency[43]. Consequently, genotyping still appears to be of no help in predicting the clinical outcome of individuals with MCC deficiency.


Our data confirm that MCC deficiency despite its low penetrance can lead to a severe clinical phenotype resembling classical organic acidurias. However, neither the genotype nor the biochemical phenotype is helpful in predicting which affected individual is at risk of developing clinical symptoms.


  1. 1.

    Sweetman L, Williams JC: Branched chain organic acidurias. In The Metabolic & Molecular Bases of Inherited Disease 8th edition. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D. 2001, McGraw Hill, New York, 2125-2163.

    Google Scholar 

  2. 2.

    Baumgartner MR, Almashanu S, Suormala T, Obie C, Cole RN, Packman S, Baumgartner ER, Valle D: The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency. J Clin Invest. 2001, 107: 495-504.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  3. 3.

    Gallardo ME, Desviat LR, Rodrígues JM, Esparza-Gordillo J, Pérez-Cerdá C, Pérez B, Rodrígues-Pombo P, Criado O, Sanz R, Morton DH, et al: The molecular basis of 3-methlcrotonylglycinuria, a disorder of leucine catabolsim. Am J Hum Genet. 2001, 68: 334-346.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  4. 4.

    Holzinger A, Roschinger W, Lagler F, Mayerhofer PU, Lichtner P, Kattenfeld T, Thuy LP, Nyhan WL, Koch HG, Muntau AC, Roscher AA: Cloning of the human MCCA and MCCB genes and mutations therein reveal the molecular cause of 3-methylcrotonyl-CoA: carboxylase deficiency. Hum Mol Genet. 2001, 10: 1299-1306.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Desviat LR, Perez-Cerda C, Perez B, Esparza-Gordillo J, Rodriguez-Pombo P, Penalva MA, Rodriguez De Cordoba S, Ugarte M: Functional analysis of MCCA and MCCB mutations causing methylcrotonylglycinuria. Mol Genet Metab. 2003, 80: 315.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Stadler SC, Polanetz R, Maier EM, Heidenreich SC, Niederer B, Mayerhofer PU, Lagler F, Koch HG, Santer R, Fletcher JM, et al: Newborn screening for 3-methylcrotonyl-CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment. Hum Mutat. 2006, 27: 748-759.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Uematsu M, Sakamoto O, Sugawara N, Kumagai N, Morimoto T, Yamaguchi S, Hasegawa Y, Kobayashi H, Ihara K, Yoshino M, et al: Novel mutations in five Japanese patients with 3-methylcrotonyl-CoA carboxylase deficiency. J Hum Genet. 2007, 52: 1040-1043.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Nguyen KV, Naviaux RK, Patra S, Barshop BA, Nyhan WL: Novel mutations in the human MCCA and MCCB gene causing methylcrotonylglycinuria. Mol Genet Metab. 2011, 102: 218-221.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Dirik E, Yis U, Pasaoglu G, Chambaz C, Baumgartner MR: Recurrent attacks of status epilepticus as predominant symptom in 3-methylcrotonyl-CoA carboxylase deficiency. Brain Dev. 2008, 30: 218-220.

    Article  PubMed  Google Scholar 

  10. 10.

    Eminoglu FT, Ozcelik AA, Okur I, Tumer L, Biberoglu G, Demir E, Hasanoglu A, Baumgartner MR: 3-Methylcrotonyl-CoA carboxylase deficiency: phenotypic variability in a family. J Child Neurol. 2009, 24: 478-481.

    Article  PubMed  Google Scholar 

  11. 11.

    Dantas MF, Suormala T, Randolph A, Coelho D, Fowler B, Valle D, Baumgartner MR: 3-Methylcrotonyl-CoA carboxylase deficiency: mutation analysis in 28 probands, 9 symptomatic and 19 detected by newborn screening. Hum Mutat. 2005, 26: 164.

    Article  PubMed  Google Scholar 

  12. 12.

    Morscher RJ, Grünert SC, Bürer C, Burda P, Suormala T, Fowler B, Baumgartner MR: A single mutation in MCCC1 or MCCC2 as a potential cause of positive screening for 3-methylcrotonyl-CoA carboxylase deficiency. Mol Genet Metab. 2012, 105: 602-606.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Naylor EW, Chace DH: Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol. 1999, 14: S4-8.

    PubMed  Google Scholar 

  14. 14.

    Koeberl DD, Millington DS, Smith WE, Weavil SD, Muenzer J, McCandless SE, Kishnani PS, McDonald MT, Chaing S, Boney A, et al: Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis. 2003, 26: 25-35.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Roscher AA, Liebl B, Fingerhut R, Olgemöller B: Prospective study of MS-MS newborn screening in Bavaria, Germany. J Inherit Metab Dis. 2000, 23: 4.

    Google Scholar 

  16. 16.

    Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF: Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003, 111: 1399-1406.

    Article  PubMed  Google Scholar 

  17. 17.

    Wilcken B, Wiley V, Hammond J, Carpenter K: Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003, 348: 2304-2312.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Visser G, Suormala T, Smit GP, Reijngoud DJ, Bink-Boelkens MT, Niezen-Koning KE, Baumgartner ER: 3-methylcrotonyl-CoA carboxylase deficiency in an infant with cardiomyopathy, in her brother with developmental delay and in their asymptomatic father. Eur J Pediatr. 2000, 159: 901-904.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Bannwart C, Wermuth B, Baumgartner R, Suormala T, Wiesmann UN: Isolated biotin-resistant deficiency of 3-methylcrotonyl-CoA carboxylase presenting as a clinically severe form in a newborn with fatal outcome. J Inherit Metab Dis. 1992, 15: 863-868.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Dodelson de Kremer R, Latini A, Suormala T, Baumgartner ER, Laróvere L, Civallero G, Guelbert N, Paschini-Capra A, Depetris-Boldini C, Mayor C: Leukodystrophy and CSF purine abnormalities associated with isolated 3-methylcrotonyl-CoA carboxylase deficiency. Metabolic Brain Disease. 2002, 17: 13-18.

    Article  Google Scholar 

  21. 21.

    Baykal T, Huner Gokcay G, Ince Z, Dantas MF, Fowler B, Baumgartner MR, Can G, Demirkol M: 3-methylcrotonyl-CoA carboxylase deficiency with early onset necrotizing encephalopathy and lethal outcome. J Inherit Metab Dis. 2005, 28: 229-233.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Gibson KM, Bennett MJ, Naylor EW, Morton DH: 3-Methylcrotonyl-coenzyme A carboxylase deficiency in Amish/Mennonite adults identified by detection of increased acylcarnitines in blood spots of their children. J Pediatr. 1998, 132: 519-523.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Baykal T, Gokcay GH, Ince Z, Dantas MF, Fowler B, Baumgartner MR, Demir F, Can G, Demirkol M: Consanguineous 3-methylcrotonyl-CoA carboxylase deficiency: early-onset necrotizing encephalopathy with lethal outcome. J Inherit Metab Dis. 2005, 28: 229-233.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    van Hove JLK, Rutledge SL, Nada MA, Kahler SG, Millington DS: 3-Hydroxyisovalerylcarnitine in 3-methylcrotonyl-CoA carboxylase defciency. J Inherit Metab Dis. 1995, 18: 592-601.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Steen C, Baumgartner ER, Duran M, Lehnert W, Suormala T, Fingerhut R, Stehn M, Kohlschütter A: Metabolic stroke in isolated 3-methylcrotonyl-CoA carboxylase deficiency. Eur J Pediatr. 1999, 158: 730-733.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Ficicioglu C, Payan I: 3-Methylcrotonyl-CoA carboxylase deficiency: metabolic decompensation in a noncompliant child detected through newborn screening. Pediatrics. 2006, 118: 2555-2556.

    Article  PubMed  Google Scholar 

  27. 27.

    Oude Luttikhuis HG, Touati G, Rabier D, Williams M, Jakobs C, Saudubray JM: Severe hypoglycaemia in isolated 3-methylcrotonyl-CoA carboxylase deficiency; a rare, severe clinical presentation. J Inherit Metab Dis. 2005, 28: 1136-1138.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Darin N, Andersen O, Wiklund LM, Holmgren D, Holme E: 3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis. Pediatr Neurol. 2007, 36: 132-134.

    Article  PubMed  Google Scholar 

  29. 29.

    Murayama K, Kimura M, Yamaguchi S, Shinka T, Kodama K: Isolated 3-methylcrotonyl-CoA carboxylase deficiency in a 15-year-old girl. Brain Devel. 1997, 19: 303.

    CAS  Article  Google Scholar 

  30. 30.

    Yap S, Monavari AA, Thornton P, Naughten E: Late infantile 3-methylcrotonyl-CoA carboxylase deficiency presenting as global developmental delay. J Inherit Metab Dis. 1998, 21: 175-176.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Friebel D, von der Hagen M, Baumgartner ER, Fowler B, Hahn G, Feyh P, Heubner G, Baumgartner MR, Hoffmann G: The first case of 3-methylcrotonyl-CoA (MCC) carboxylase deficiency responsive to biotin. Neuropediatrics. 2006, 37: 72-78.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Ihara K, Kuromaru R, Inoue Y, Kuhara T, Matsumoto I, Yoshino M, Fukushige J: An asymptomatic infant with isolated 3-methylcrotonyl-coenzyme: A carboxylase deficiency detected by newborn screening for maple syrup urine disease. Eur J Pediatr. 1997, 156: 713-715.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Beemer FA, Bartlett K, Duran M, Ghneim HK, Wadman SK, Bruinvis L, Ketting D: Isolated biotin-resistant 3-methylcrotonyl-CoA carboxylase deficiency in two sibs. Eur J Pediatr. 1982, 138: 351-354.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Mourmans J, Bakkeren J, de Jong J, Wevers R, van Diggelen OP, Suormala T, Baumgartner R, Wendel U: Isolated (biotin-resistant) 3-methylcrotonyl-CoA carboxylase deficiency: Four sibs devoid of pathology. J Inherit Metab Dis. 1995, 18: 643-645.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Pearson MA, Aleck KA, Heidenreich RA: Benign clinical presentation of 3-methylglycinuria. J Inherit Metab Dis. 1995, 18: 640-641.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Arnold GL, Koeberl DD, Matern D, Barshop B, Braverman N, Burton B, Cederbaum S, Fiegenbaum A, Garganta C, Gibson J, et al: A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab. 2008, 93: 363-370.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Boneh A, Baumgartner M, Hayman M, Peters H: Methylcrotonyl-CoA carboxylase (MCC) deficiency associated with severe muscle pain and physical disability in an adult. J Inherit Metab Dis. 2005, 28: 1139-1140.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Pinto L, Zen P, Rosa R, Paskulin G, Perla A, Barea L, Baumgartner MR, Dantas MF, Fowler B, Giugliani R, et al: Isolated 3-methylcrotonyl-coenzyme A carboxylase deficiency in a child with metabolic stroke. J Inherit Metab Dis. 2006, 29: 205-206.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Wolfe LA, Fiegold DN, Vockley J, Walters N, Chambaz C, Suormala T, Koch HG, Matern D, Barshop BA, Cropcho LJ, Baumgartner MR, Gibson KM: Potential misdiagnosis of 3-methylcrotonyl-CoA carboxylase deficiency associated with absent or trace urinary 3-methylcrotonylglycine. Pediatrics. 2007, 120: e1135-e1340.

    Article  Google Scholar 

  40. 40.

    Suormala T, Wick H, Bonjour JP, Baumgartner ER: Rapid differential diagnosis of carboxylase deficiencies and evaluation for biotin-responsiveness in a single blood sample. Clin Chim Acta. 1985, 145: 151-162.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Stucki M, Suormala T, Fowler B, Valle D, Baumgartner MR: Cryptic exon activation by disruption of exon splice enhancer: novel mechanism causing 3-methylcrotonyl-CoA carboxylase deficiency. J Biol Chem. 2009, 284: 28953-28957.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  42. 42.

    Ensenauer R, Vockley J, Willard JM, Huey JC, Sass JO, Edland SD, Burton BK, Berry SA, Santer R, Grunert S, et al: A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet. 2004, 75: 1136-1142.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  43. 43.

    Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B, Busch U, Krone N, v Kries R, Roscher AA: Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat. 2005, 25: 443-452.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Baumgartner MR, Dantas MF, Suormala T, Almashanu S, Giunta C, Friebel D, Gebhardt B, Fowler B, Hoffmann GF, Baumgartner ER, Valle D: Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele-specific dominant negative effect and responsiveness to biotin therapy. Am J Hum Genet. 2004, 75: 790-800.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  45. 45.

    Jitrapakdee S, Wallace JC: The biotin enzyme family: conserved structural motifs and domain rearrangements. Current Protein Pept Sci. 2003, 4: 217-229.

    CAS  Article  Google Scholar 

  46. 46.

    Huang CS, Ge P, Zhou ZH, Tong L: An unanticipated architecture of the 750-kDa alpha(6)beta(6) holoenzyme of 3-methylcrotonyl-CoA carboxylase. Nature. 2011, 481: 219-223.

    PubMed Central  Article  PubMed  Google Scholar 

Download references


We thank the following doctors and physicians for providing clinical information: Dr. M. Du Moulin (Münster, Germany), Prof. Dr. A. Das (Hannover, Germany), Dr. Konstantinos Tsiakas (Hamburg, Germany), Prof. Dr. F. Trefz (Reutlingen, Germany), Prof. Dr. J. Kreuder (Gießen, Germany), Dr. P. Hofstetter (Wiesbaden, Germany), Dr. B. Müksch (Köln, Germany), Dr. S. Beblo (Leipzig, Germany), Dr. C. Prasad (London, Canada), Dr. M. Schiff (Paris, France), Prof. Dr. A. Burlina (Padova, Italy), Dr. N. Darin (Göteborg, Sweden), Dr. Hanna Mandel (Haifa, Israel), Dr. F.S. Ezgü (Ankara, Turkey), Dr. D. Lianou-Trapezanoglou (Athens, Greece), Dr. N. Al Sannaà (Dhahran, Saudi Arabia), Dr. Y.H. Chien (Taipei, Taiwan), Dr. L. Lapagesse (Porto Alegre, Brazil), Dr. S. Cederbaum (Los Angeles, USA) and Dr. G. Horvath (Vancouver, Canada). We are also grateful to all physicians who referred patient samples to our laboratory.

Sarah C. Grünert was supported by the Deutsche Forschungsgemeinschaft, Grant GR 3918/1-1. Martin Stucki was supported by the Swiss National Science Foundation Grant 32003AO-109219. Additional financial support of this work was provided by personal research grants dedicated to K.O. Schwab.

Author information



Corresponding author

Correspondence to Matthias R Baumgartner.

Additional information

Competing interests

All authors declare that they have no competing interests.

Authors' contributions

SCG collected and interpreted clinical data, performed expression studies and Western blot experiments and drafted the manuscript; MS, RJM and PB were involved in expression studies and Western blot experiments; TS and BF performed enzyme assays and revised the manuscript; CB carried out the molecular genetic studies; EC, CF, JH, SK, DM, EP, RS, KOS and BW contributed clinical patient data and revised the manuscript; WWY performed sequence alignments and in silico prediction of mutations. He also revised the manuscript; MRB designed the study, was involved in the collection of data, analyzed and interpreted data and drafted/revised the manuscript. All authors read and approved the final manuscript.

Electronic supplementary material

Figure S1.

Additional file 1: Amino acid sequence alignment of human MCCC1. Amino acid sequence alignment of human MCCC1 (hMCCC1, Uniprot Q96RQ3), as well as the structurally characterized P. aeruginosa MCCC1 (paMCCC1, Q9I299), Ruegeria pomeroyi PCCα (bPCCA, Q5LUF3), human ACC1 (hACC1, Q13085) and ACC2 (hACC2, O00763). Novel MCCC1 missense mutations are asterisked. The electrostatic interaction between Glu288 and Arg444 in MCCC1 is highlighted in green. (TIFF 17 MB)

Figure S2.

Additional file 2: Amino acid sequence alignment of human MCCC2.Amino acid sequence alignment of human MCCC2 (hMCCC2, Uniprot Q9HCC0), as well as the structurally characterized P. aeruginosa MCCC2 (paMCCC2, Q9I297), Propionibacterium shermanii methylmalonyl-CoA carboxyltransferase (psMMCC, Q8GBW6), Streptomyces coelicolor PCCβ (scPCCB, Q9X4K7) and Roseobacter denitrificans PCCα (bPCCA, Q168G2). Novel MCCC2 missense mutations are asterisked. (TIFF 18 MB)

Authors’ original submitted files for images

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Grünert, S.C., Stucki, M., Morscher, R.J. et al. 3-methylcrotonyl-CoA carboxylase deficiency: Clinical, biochemical, enzymatic and molecular studies in 88 individuals. Orphanet J Rare Dis 7, 31 (2012).

Download citation


  • 3-Methylcrotonyl-CoA carboxylase
  • MCCC1
  • MCCC2
  • Biotin
  • Inborn error
  • Organic aciduria
  • Newborn screening